SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Zim $4.5 billion bidder faces foreclosure on his home

NextVision insiders cash out $200 million in share sale

"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"

Electra Real Estate CEO: “The $7 trillion US rental housing market is the place to be”

Buzz

Most popular

Daily

Weekly

1

Jewish family from Mexico donates NIS 200 million to establish Israel's largest rehabilitation hospital

2

After raising $20 million, collapsed startup Swish.ai sells to Unframe for just $150,000

3

Echo: “Employees have become very good at identifying performative culture”

4

After PTSD and years of insomnia, Israeli founder raises $6.5 million to improve sleep through scent

5

More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life

Merck

6 stories about Merck

Remepy founders

Merck KGaA and Remepy partner to test ‘Hybrid Drugs’ model

28.04.26|Meir Orbach

Collaboration explores combining medication with app-based therapies in rare tumor programs.

Biolojic Design lands drug discovery collaboration with Merck potentially worth up to 346 million euros

03.06.24|Sophie Shulman

The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.

ד״ר צחון בנטואיץ׳ מייסד משותף של קיוריס Quris AI

Pharma giant Merck expands collaboration with Quris-AI

28.09.23|Meir Orbach

This follows the successful initial collaboration, a preclinical study to assess Quris-AI’s ability to predict drug toxicity in comparison to traditional in vitro and in vivo approaches

מוסף שבועי 18.5.23 פרופסור גל מרקל

Israeli biotech phenom puts death knell on cancer

21.05.23|Roni Dori

At 44, Gal Markel is a biotech bulldozer. After a $95 million exit, the professor of immunology serves as the Deputy Director General of Beilinson Hospital and the Director of the Davidoff Cancer Center, and is also involved in five startups. Now he has raised around $33 million to establish the Samueli Institute, researching ways to help the immune system eradicate cancer cells

“Pharma companies need to capitalize on early-stage breakthrough innovation.”

Collaboration is key for pharmaceutical companies as they seek to make the drug development process more efficient and successful, says Larisa Amir, managing director of Merck’s R&D Center.

Larisa Amir appointed Managing Director of Merck R&D Center in Israel

Amir will be responsible for managing the center and will also focus on in-house innovation and external scouting for technologies and biotechnology capabilities in Israeli startups, academia, and hospitals